LUMINA is an advanced minimal residual disease detection platform for lung cancer that harnesses the power of multi-omics biomarkers and AI
LOS ANGELES and AMSTERDAM, December 23, 2024 (GLOBE NEWSWIRE) — Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapy powered by artificial intelligence, today announced its subsidiary RenovaroCube (the ‘Cube’)a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, together with its consortium partners Flomics Biotech, Uppsala Universitet and Oncodia, has been approved for grant funding for the Lumina project from the Eurostars funding program following review by a independent expert panel.
Eurostars is part of the European Partnership for Innovative SMEs (small and medium-sized enterprises). The partnership is co-financed by the European Union through Horizon Europe. Eurostars is the largest international financing program for SMEs wanting to collaborate on R&D projects that create innovative products, processes or services for commercialization, with an expected annual public-private investment of more than €250 million.
The Lumina project aims to develop an advanced Minimal Residual Disease (MRD) detection platform for lung cancer. Harnessing the power of multi-omics biomarkers and AI-driven technology, this platform aims to transform recurrence risk prediction and treatment strategies for millions of patients worldwide.
“This award further validates our purpose-built AI platform in facilitating the discovery of biomarkers critical to the early detection, monitoring and personalization of cancer,” said David Weinstein, Chief Executive Officer of Renovaro. “In collaboration with leading institutions and companies, including Uppsala University, Oncodia AB and Flomics Biotech, the Lumina project aims to improve the survival of lung cancer patients. More than 5.7 million cases of lung cancer are treated or monitored worldwide every year, and 60% of all curatively treated lung cancer patients will relapse. Lumina represents an important opportunity to address this critical issue, and we look forward to continuing to work with our partners to bring this product to market.”
A powerful platform for better results
The goal of the LUMINA project is to develop an advanced platform designed to provide unparalleled accuracy in detecting minimal residual disease. To achieve this, liquid biopsies in combination with multi-omics biomarker technology represent a revolutionary approach. The LUMINA project’s AI-powered platform takes advantage of this potential and aims to provide a highly accurate, non-invasive solution that addresses a critical unmet need in lung cancer care.
Collaborative expertise
The LUMINA project is built on a strong foundation of collaboration with leading institutions and companies, including Uppsala University, Oncodia AB and Flomics Biotech. These partnerships bring together world-class clinical expertise and a multi-omic approach, utilizing the analysis of cell-free DNA and RNA to ensure the success of the platform.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity, enabled by mutually reinforcing AI and biotechnology platforms for early diagnosis, better targeted treatments and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell gene immunotherapy business and RenovaroCube.
About RenovaroCube
RenovaroCube is a pioneer in AI-based molecular diagnostics and is committed to revolutionizing healthcare through advanced data analytics. The platform integrates advanced AI capabilities with state-of-the-art HPC infrastructure to deliver unparalleled insights into multi-omic data for early disease detection based on non-invasive testing using liquid biopsy (blood).
RenovaroCube’s AI platform is purpose-built for processing and analysis multi-omic molecular datafacilitating the discovery of biomarkers critical for the early detection, monitoring and personalization of treatments. Originally developed for the fintech sector, this platform is being redesigned for healthcare and offers:
- Sequence Processing: Transform raw molecular data from patient samples into clean, analysable formats using advanced sequencing and alignment technologies, ensuring the highest quality for downstream analysis.
- Biomarker discovery: Leverage unique algorithms and multi-omic pipelines to identify biologically relevant cancer biomarkers, providing critical insights into disease mechanisms and potential therapeutic targets.
- AI factory: Use advanced machine learning models to predict the presence, origin and stage of cancer based on extracted biomarker features. These models are trained on large datasets to improve accuracy and reliability and support early detection and personalized treatment strategies.
- Precision diagnostics: Provide an interactive interface for visualizing data, generating comprehensive clinical reports and delivering actionable insights across omic layers and biomarkers. This interface enables healthcare professionals to make informed decisions with confidence.
About Flomics Biotech, SL
Flomics is a fast-growing biotech company based in Barcelona, active in the field of genomics and liquid biopsy. The goal of Flomics is to develop a revolutionary diagnostic blood test based on Next-Generation Sequencing (NGS) of cell-free RNA, suitable for the early detection of various complex diseases, in particular cancer. In addition, Flomics, as CRO, also offers the following services: discovery of biomarkers (on tissue and biofluids), support in bioinformatic analysis and an intuitive web-based platform suitable for the analysis of NGS data (Stratus). The Flomics team has a strong background in RNA and liquid biopsy, as well as advanced bioinformatics analysis methods.
About Uppsala University
Uppsala University is the first university in the Nordic countries and a world-class research institution. The Department of Immunology, Genetics and Pathology focuses on advancing the diagnosis and treatment of cancer through the study of molecular changes associated with cancer. The research aims to leverage measurable molecular information to improve diagnosis and therapy, with a strong focus on the development of liquid biopsy-based diagnostic tests. A key initiative is the U-CAN project, which provides a unique biobank of high-quality clinical samples and data from cancer patients to support translational research. This effort, combined with cutting-edge molecular biology and clinical expertise, underscores the university’s commitment to transforming cancer care.
About Oncodia AB
Oncodia is an innovative medical technology company based in Uppsala, Sweden. Oncodia is committed to providing in vitro diagnostic products that consistently meet customer needs, improve patient treatment outcomes, and meet regulatory and regulatory requirements. Oncodia provides CE/IVD software for precision cancer medicine, as well as CE/IVD products for DNA/RNA isolation from diagnostic tissue specimens. Their focus is to provide clinical pathology and oncology with the right solutions for optimal molecular diagnostics of solid tumors.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or effectiveness of our pipeline, platform and fundraising. All statements other than statements of historical fact are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “intends,” “intends,” “potential.” or similar expressions. Actual events or results may differ materially from those projected in such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group – MZ North America
949-491-8235
[email protected]
www.mzgroup.us
For media inquiries please contact:
[email protected] And [email protected]
